LeonaBio

LeonaBio EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of LeonaBio (LONA) as of Oct 16, 2026 is -0.91. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -0.92 — a change of -1.33% (higher).

EV/EBIT

-0.91

YoY

-1.33%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of LeonaBio is 2025 -0.91 . EV/EBIT (Enterprise Value to EBIT) of LeonaBio was 2024 -0.92 . It decreases by -1.33% higher compared to the previous year.

The LeonaBio EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2018
-18.51 USD
Jan 1, 2019
-17.01 USD
Jan 1, 2020
-4.64 USD
Jan 1, 2021
-1.45 USD
Jan 1, 2022
-0.89 USD
Jan 1, 2023
-0.74 USD
Jan 1, 2024
-0.92 USD
Jan 1, 2025
-0.91 USD
The LeonaBio EV/EBIT history
YEAREV/EBITYoY
-0.91-1.33%
-0.92+24.34%
-0.74-17.10%
-0.89-38.45%
-1.45-68.77%
-4.64-72.75%
-17.01-8.07%
-18.51—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

LeonaBio Stock analysis

What does LeonaBio do? LeonaBio Inc, trading under the ticker LONA with ISIN US04746L2034, is a U.S.-based company headquartered in Bothell, Washington. Operating within the Health Care sector, specifically in the Pharmaceuticals industry, the company has a workforce of 20 employees. LeonaBio Inc. completed its initial public offering (IPO) on September 18, 2020. The company's website is https://www.athira.com/. It is important to note that the provided source description refers to Athira Pharma, Inc., which appears to be a different entity from LeonaBio Inc. The source description mentions a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, with a pipeline built from an ATH platform. However, these details are not confirmed as part of LeonaBio Inc. and should not be attributed to it. The company's actual business focus, product pipeline, or technological platforms are not specified in the provided information. LeonaBio Inc. is a publicly traded company with a small team, operating in the pharmaceutical space, but specific details about its products, research, or development activities are not included in the facts provided. LeonaBio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about LeonaBio stock

EV/EBIT (Enterprise Value to EBIT) of LeonaBio is -0.91 in 2025.

EV/EBIT (Enterprise Value to EBIT) of LeonaBio changed from -0.92 to -0.91, representing a -1.33% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) LeonaBio since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s LeonaBio with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — LeonaBio

All Key Metrics — LeonaBio